原題
Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial.

Journal: J Clin Oncol (CiteScore 2022: 39.6)
DOI: 10.1200/JCO.24.01119
PMID: 40408613